Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.

ABSTRACT:

Background

Immunotherapy with immune checkpoint inhibitors has radically changed the management of a broad spectrum of tumors. In contrast, only very limited information is available about the efficacy of these therapies in non-melanoma skin cancers, especially in basal cell carcinoma. The latter malignancy is often associated with both an impairment of the host immune response and a high mutation burden, suggesting that immune checkpoint inhibitor-based immunotherapy may be effective in the treatment of this tumor.

Case presentation

A 78-year-old woman was diagnosed with a metastatic non-small-cell-lung-cancer. Following the lack of response to two lines of systemic chemotherapy, she was treated with the anti-PD-1 monoclonal antibody nivolumab, obtaining a prolonged stable

SUBMITTER: Sabbatino F 

PROVIDER: S-EPMC6247622 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature